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Background: Recent studies showed that some statins may impair glucose metabolism. In a reanalysis of WOSCOPS, individual risk of diabetes 
with pravastatin was reported as null. Limited information is available on the glycemic effect of a recently approved statin, pitavastatin. The objective 
of this prespecified safety analysis was to assess the effects of pitavastatin 4 mg vs pravastatin 40 mg on markers of glucose metabolism in PREVAIL 
US, a 12-week, randomized, double-blind Phase 4 trial in a general population with primary hyperlipidemia or mixed dyslipidemia.
Methods: Fasting plasma glucose, fasting plasma insulin, and HbA1c data were prospectively collected as part of the PREVAIL US study comparing 
pitavastatin 4 mg (n=164) with pravastatin 40 mg (n=164) in patients with primary hyperlipidemia or mixed dyslipidemia (mean age 58 yrs, 
~50% men, mean weight 86 kg, mean body mass index 30 kg/m2). An ANCOVA model was used for the analysis of change in glucose metabolism 
parameters including homeostasis model assessment of insulin resistance (HOMA-IR) and quantitative insulin-sensitivity check index (QUICKI) from 
baseline to Week 12 as the dependent variable, treatment and region as factors, and baseline values of the dependent variables as the covariates.
Results: A significantly greater reduction in low-density lipoprotein cholesterol (LDL-C) was seen with pitavastatin 4 mg compared to pravastatin 
40 mg (difference in median percent reduction = 12.5%, p<0.0001). No clinically relevant changes from baseline in glucose metabolism were noted 
at 12 weeks with pitavastatin or pravastatin, respectively: fasting plasma glucose (-0.3 mg/dL and -1.2 mg/dL), fasting plasma insulin (0.3 μIU/mL 
and -1.0 μIU/mL), HbA1c (0.08% and 0.02%), HOMA-IR (0.05 and -0.44), and QUICKI (0 and 0.001).
Conclusions: While pitavastatin 4 mg provided significantly greater reduction in LDL-C compared to pravastatin 40 mg after 12 weeks of therapy 
in patients with primary hyperlipidemia or mixed dyslipidemia, neither statin had clinically relevant effects on glucose metabolism.
